Exploring the link between FODMAPs and Graft Versus Host Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the relationship between FODMAPs and Graft Versus Host Disease (GVHD) in patients who have undergone bone marrow transplantation. It involves collecting fecal samples from successfully transplanted patients and analyzing the degradation rate of FODMAPs after 24 hours of culture. The study will observe how this degradation rate correlates with the timing and severity of GVHD. By understanding this relationship, the study seeks to provide insights into dietary impacts on GVHD outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinical diagnosis of "AML","ALL","MDS" or "MM" Disease;
2. Must be treated with bone marrow transplantation;
3. The transplanted bone marrow was successfully planted

Exclusion Criteria:

1. Gastrointestinal diseases；
2. Age\>60; or Age\<10；
3. Probiotics or prebiotics were taken before enrollment

Where it's running

• 中国
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: xiaofei qi
• Email: qixf-sz@hotmail.com
• Phone: +13812616208

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Ruxolitinib to prevent complications after haploidentical stem cell transplants

  This study is testing if the drug Ruxolitinib can help prevent complications like graft-versus-host disease in patients receiving stem cell transplants from partially matched donors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06008808

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• Ruxolitinib for Graft-Versus-Host Disease in Clinical Practice

  This study tests how well Jakavi (ruxolitinib) works and how safe it is for people with acute or chronic GVHD being treated in real-world medical settings.

  Recruiting Novartis · Tokyo · NCT07594587

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.